Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.

The correlation between telomerase activity and human tumors has led to the hypothesis that tumor growth requires reactivation of telomerase and that telomerase inhibitors represent a class of chemotherapeutic agents. Herein, we examine the effects of inhibition of telomerase inside human cells. Peptide nucleic acid and 2'-O-MeRNA oligomers inhibit telomerase, leading to progressive telomere shortening and causing immortal human breast epithelial cells to undergo apoptosis with increasing frequency until no cells remain. Telomere shortening is reversible: if inhibitor addition is terminated, telomeres regain their initial lengths. Our results validate telomerase as a target for the discovery of anticancer drugs and supply general insights into the properties that successful agents will require regardless of chemical type. Chemically similar oligonucleotides are in clinical trials and have well characterized pharmacokinetics, making the inhibitors we describe practical lead compounds for testing for an antitelomerase chemotherapeutic strategy.

[1]  D. Corey,et al.  Telomerase inhibition by peptide nucleic acids reverses `immortality' of transformed human cells , 1999, Oncogene.

[2]  T. Jacks,et al.  For Better or Worse? Telomerase Inhibition and Cancer , 1999, Cell.

[3]  R. Hogrefe.  An antisense oligonucleotide primer. , 1999, Antisense & nucleic acid drug development.

[4]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[5]  T. Cech,et al.  Telomerase and the maintenance of chromosome ends. , 1999, Current opinion in cell biology.

[6]  D. Corey,et al.  Cellular delivery of peptide nucleic acids and inhibition of human telomerase. , 1999, Chemistry & biology.

[7]  L. Chin,et al.  Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse , 1999, Cell.

[8]  Lynda Chin,et al.  p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis , 1999, Cell.

[9]  R. Wheelhouse,et al.  Interactions of TMPyP4 and TMPyP2 with Quadruplex DNA. Structural Basis for the Differential Effects on Telomerase Inhibition , 1999 .

[10]  D. Corey,et al.  Automated synthesis of peptide nucleic acids and peptide nucleic acid-peptide conjugates. , 1999, Analytical biochemistry.

[11]  Sandy Chang,et al.  Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice , 1999, Cell.

[12]  C. A. Stein,et al.  Keeping the biotechnology of antisense in context , 1999, Nature Biotechnology.

[13]  M. Blasco,et al.  Telomere shortening in mTR−/− embryos is associated with failure to close the neural tube , 1999, The EMBO journal.

[14]  W. Hahn,et al.  Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Agrawal,et al.  Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. , 1998, Bioorganic & medicinal chemistry letters.

[16]  D. Corey,et al.  Inhibition of human telomerase by 2'-O-methyl-RNA. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Yedy Israel,et al.  Tetranucleotide GGGA Motif in Primary RNA Transcripts , 1998, The Journal of Biological Chemistry.

[18]  C. Marwick,et al.  First "antisense" drug will treat CMV retinitis. , 1998, JAMA.

[19]  R. DePinho,et al.  Essential role of mouse telomerase in highly proliferative organs , 1998, Nature.

[20]  S. Benchimol,et al.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span , 1998, Current Biology.

[21]  D. Wallwiener,et al.  Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer , 1998, International journal of cancer.

[22]  C. Harley,et al.  Extension of life-span by introduction of telomerase into normal human cells. , 1998, Science.

[23]  E. Dmitrovsky,et al.  High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. , 1997, Journal of the National Cancer Institute.

[24]  S. Bacchetti,et al.  Reprogramming of telomerase by expression of mutant telomerase RNA template in human cells leads to altered telomeres that correlate with reduced cell viability , 1997, Molecular and cellular biology.

[25]  R. Reddel,et al.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines , 1997, Nature Medicine.

[26]  J. Guillem,et al.  Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  María A Blasco,et al.  Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.

[28]  S. Neidle,et al.  Inhibition of human telomerase by a G-quadruplex-interactive compound. , 1997, Journal of medicinal chemistry.

[29]  J. Shay,et al.  Telomerase activity in ordinary meningiomas predicts poor outcome. , 1997, Human pathology.

[30]  J. Shay,et al.  Clinical implications of telomerase activity levels in acute leukemia. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  S. Agrawal,et al.  Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  C. Autexier,et al.  Telomerase and cancer: revisiting the telomere hypothesis. , 1996, Trends in biochemical sciences.

[33]  J. Shay,et al.  Comparison of the telomeric repeat amplification protocol (TRAP) to the new TRAP-eze telomerase detection kit , 1996 .

[34]  B. Gallie,et al.  Development of retinoblastoma in the absence of telomerase activity. , 1996, Journal of the National Cancer Institute.

[35]  E. Blackburn,et al.  Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines , 1996, Molecular and cellular biology.

[36]  J. Shay,et al.  Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[38]  E. Blackburn,et al.  Runaway telomere elongation caused by telomerase RNA gene mutations , 1995, Nature.

[39]  Keiko Hiyama,et al.  Correlating telomerase activity levels with human neuroblastoma outcomes , 1995, Nature Medicine.

[40]  L. Gollahon,et al.  Spontaneous in vitro immortalization of breast epithelial cells from a patient with Li-Fraumeni syndrome , 1995, Molecular and cellular biology.

[41]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[42]  D. Gottschling,et al.  TLC1: template RNA component of Saccharomyces cerevisiae telomerase. , 1994, Science.

[43]  C. Harley,et al.  Telomerase activity in human ovarian carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Blackburn,et al.  An alternative pathway for yeast telomere maintenance rescues est1− senescence , 1993, Cell.

[45]  M. Egholm,et al.  Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. , 1991, Science.

[46]  E. Blackburn,et al.  In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs , 1990, Nature.

[47]  G. Morin.  The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats , 1989, Cell.